Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory University
WP1066 demonstrates activity in DIPG, rare form of pediatric brain tumor HOUSTON, Oct. 1, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...
Moleculin Announces Discovery of Significant In Vitro Activity Against COVID-19 Virus for New Antimetabolites
Increases antiviral drug candidates to threeHOUSTON, Sept. 29, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the...
Moleculin Announces COVID-19 In Vivo Testing Contracted for WP1122
Additional In Vitro Testing Has Also BegunHOUSTON, Sept. 14, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and...
Moleculin to Present at Upcoming Healthcare Investor Conferences
HOUSTON, Sept. 10, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of...
Moleculin Announces Successful Completion of Pre-IND Meeting with the FDA
Intends to file an IND using Annamycin for the Treatment of Soft Tissue Sarcomas with Lung Metastases by Year-EndHOUSTON, Sept. 9, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad...
Moleculin to Present at LD Micro 500 Virtual Investor Conference
HOUSTON, Aug. 27, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp, Chairman and Chief...
Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended June 30, 2020
HOUSTON, Aug. 12, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced its financial results for the...
Additional Independent Research Further Supports Glucose Metabolism as Important COVID-19 Target
Research findings provide further scientific support for the mechanism of action of Moleculin's prodrug WP1122HOUSTON, July 29, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad...
Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus
HOUSTON, July 21, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a second round of...
Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate
HOUSTON, July 15, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has entered into...